braun tall getty

Report: Alex Rodriguez, Ryan Braun among players MLB seeks to suspend for Biogensis connection

124 Comments

Performance-enhancing drugs loomed large entering the baseball season, amid reports that dozens of players — many of them high-profile stars — could be suspended because of their reported involvement with a clinic that supplied PEDs.

That story just got bigger.

From ESPN.com investigative reporters T.J. Quinn, Pedro Gomez and Mike Fish:

Major League Baseball will seek to suspend about 20 players connected to the Miami-area clinic at the heart of an ongoing performance-enhancing drug scandal, including Alex Rodriguez and Ryan Braun, possibly within the next few weeks, “Outside the Lines” has learned. If the suspensions are upheld, the performance-enhancing drug scandal would be the largest in American sports history.

Tony Bosch, the former director of the Miami-based Biogenesis clinic, is “expected to begin meeting with officials — and naming names — within a week,” according to the ESPN.com report. A source familiar with the case confirmed to The Associated Press early Wednesday morning that Bosch has indeed agreed to talk to MLB about players linked to PEDs, and that Bosch’s information could lead to suspensions. The suspensions could be issued within two weeks, though there’s likely to be an appeals process and that may take a few months.

NBCSports.com reached both Major League Baseball and the Players’ Association on Tuesday night, but both declined to comment. Terry Fahn, Rodriguez’s publicist as of January, said to contact New York publicist Ron Berkowitz; Berkowitz declined to comment when reached by phone.

MORE: A closer look at the players facing potential suspensions

The commissioner’s office will be seeking 100-game punishments for Braun and A-Rod because they both committed two offenses — the initial doping and then lying to Major League Baseball officials. The typical punishment for first-time performance-enhancing drug offenders is a 50-game suspension.

Nationals left-hander Gio Gonzalez is not a candidate for suspension, according to Quinn, because Bosch is expected to confirm to the investigators that Gio only bought league-approved substances. Some of the other names that were found in the Biogenesis documents: Melky Cabrera, Bartolo Colon, Yasmani Grandal, Nelson Cruz, Francisco Cervelli, Jesus Montero, Jhonny Peralta, Cesar Puello, Fernando Martinez, Everth Cabrera, Fautino de los Santos and Jordan Norberto.

MORE: Why a mass suspension would be a mass fail

The Biogenesis news broke in late January, when it was reported by multiple outlets that Major League Baseball was investigating Bosch under the suspicion that his clinic represented “ground zero” for performance enhancing drugs in Florida, where a disproportionate number of major leaguers grew up, played amateur and college baseball or where they currently make their offseason homes. On January 29, the Miami New Times obtained and published a large portion of the Biogenesis clinic’s records which contained the names of several major leaguers accompanied in many cases by notations which suggested that the players were given performance enhancing drugs. The documents were not conclusive of any player’s use and, in some cases — like with Gio Gonzalez — no connection could be found between the player and any substances which are banned by Major League Baseball.

Immediately after the Miami New Times report came out all of the players involved either denied any involvement with Biogenesis whatsoever or denied that they obtained banned substances.  For example, Gonzalez claims that his father was a patient of Bosch’s. Ryan Braun claims that his attorneys used Bosch as a consultant in his successful 2012 appeal of his PED suspension. Despite the denials, the report and the documents set off a media firestorm which caused Major League Baseball to step up its investigation of the players named therein.

Jacob deGrom open to extension with Mets

New York Mets starting pitcher Jacob deGrom talks during media day for the Major League Baseball World Series against the Kansas City Royals Monday, Oct. 26, 2015, in Kansas City, Mo. (AP Photo/Charlie Riedel)
AP Photo/Charlie Riedel
Leave a comment

The Mets are currently enjoying the spoils of the best young rotation in the game, but the big question is whether this is just a brief window or the start of sustained success. Given the huge prices on the free agent market, it’s going to be next to impossible to keep the band together, but at least one member of the rotation is open to sticking around for the long-term.

While there haven’t been any talks yet, All-Star right-hander Jacob deGrom told Kevin Kernan of the New York Post that he could see himself discussing an extension with the Mets.

“I’m a little bit older, so I might be more willing to do something like that,’’ deGrom told The Post at Mets pre-camp. “You just have to look at what is fair so both sides get a decent deal. It’s something I’d have to look into and make sure I agree with it.’’

It makes sense from deGrom’s perspective. He broke into the majors later than most prospects, so he’ll be 28 this June. Depending on whether he qualifies as a Super Two, he’ll be arbitration-eligible for the first time after either 2016 or 2017. Either way, he’s under team control through 2020, which means that he’s currently on track to hit free agency after his age-32 season. The market might not be kind to him even if he manages to stay healthy, so it could behoove him to get as much guaranteed money as possible right now. The Mets could always decide to play things year-to-year, but perhaps deGrom would be willing to settle for a discount in order to get them to buy out a free agent year or two. It’s a really interesting situation to think about, but odds are the two sides will wait on contract talks until he’s arbitration-eligible for the first time.

DeGrom owns a 2.61 ERA in 52 starts over his first two seasons in the majors. Among starters, only Zack Greinke, Jake Arrieta, and Clayton Kershaw have a lower ERA since the start of 2014.

Royals, Mike Moustakas avoid arbitration with two-year deal

Kansas City Royals' Mike Moustakas celebrates after hitting an RBI single against the Toronto Blue Jays during the eighth inning in Game 2 of baseball's American League Championship Seriesagainst the Toronto Blue Jays  on Saturday, Oct. 17, 2015, in Kansas City, Mo. (Nathan Denette/The Canadian Press via AP) MANDATORY CREDIT
Nathan Denette/The Canadian Press via AP
1 Comment

The Royals and third baseman Mike Moustakas have avoided arbitration by agreeing to a two-year, $14.3 million deal, reports Jon Heyman of MLB Network.

The deal, which was initially discussed last month, buys out Moustakas’ final two years of arbitration. Jeffrey Flanagan of MLB.com reports that it’s believed he’ll make $5.6 million in 2016 and $8.7 million in 2017.

The 27-year-old Moustakas posted an underwhelming .668 OPS over his first four seasons in the majors, but he enjoyed a big postseason in 2014 before breaking out last season by batting .284/.348/.470 with 22 home runs and 82 RBI.

Report: Rays having “advanced talks” with free agent reliever Tommy Hunter

Baltimore Orioles relief pitcher Tommy Hunter throws to the Miami Marlins during the seventh inning of a baseball game in Miami, Friday, May 22, 2015. (AP Photo/J Pat Carter)
AP Photo/J Pat Carter
Leave a comment

ESPN’s Jerry Crasnick reported this morning that free agent reliever Tommy Hunter required core muscle repair surgery earlier this offseason. Coming off a disappointing 2015, it’s understandable why he’s still on the market, but it sounds like he has at least one significant lead.

Marc Topkin of the Tampa Bay Times hears that the Rays are having “advanced talks” with Hunter as they attempt to add an experienced arm to their bullpen. Nothing is considered close and Hunter is also talking to other clubs. Meanwhile, the Rays have been in touch with veteran reliever Ryan Webb while monitoring the trade market.

Hunter posted a 2.88 ERA as a late-inning arm from 2013-2014, but he compiled a mediocre 4.18 ERA over 58 appearances last season between the Orioles and Cubs. On the bright side, his velocity has held steady and his control is still very good. Despite the down year and core muscle surgery, Topkin writes that Hunter may be holding out for a multi-year deal.

Pirates sign left-hander Cory Luebke

Cory Luebke Getty
Photo by Doug Pensinger/Getty Images
Leave a comment

Eric O'Flaherty wasn’t the only reclamation project added by the Pirates today, as the club also announced that they have signed left-hander Cory Luebke to a minor league contract with an invitation to spring training.

Luebke once looked like a solid rotation piece for the Padres, but he hasn’t thrown a pitch in the majors since April 27, 2012. He’s undergone a pair of Tommy John surgeries since. Now 30 years old, he logged seven innings in the minors last season before requiring a procedure to remove loose bodies around a nerve in his forearm. The Padres cut ties with him in November after declining a $7.5 million club option for 2016.

It’s hard to count on much from Luebke at this point, but he told Adam Berry of MLB.com that he feels healthy and hopes to compete for a bullpen job in the spring.